Sydney Lepkin

Novo Nordisk then sued him for patent infringement and now has withdrawn that suit.

Sydney Lepkin, NPR News.

The Danish drug company Novo Nordisk now charges more than $1,000 a month for its blockbuster drugs Ozempic and Wegovy.

That's the list price, the one that plays a role in which drugs insurers choose to cover and what the patient ultimately pays out of pocket at the pharmacy counter.

Starting in 2027, the list price for the drugs will drop to $675 for a month's supply.

That's also when lower negotiated prices for Medicare kick in.

The company already offers discounts for patients paying cash.

but those prices aren't changing for now.

Novo Nordisk's pricing announcement follows disappointing study results for its experimental new obesity drug, which caused its shares to drop 16 percent on Monday.

Sydney Lepkin, NPR News.

The FDA rattled the biotech industry when it said it wouldn't even look at Moderna's application to market the first mRNA flu shot.

Moderna used its mRNA technology to swiftly create and manufacture its COVID-19 shot during the pandemic.

The company wants to use the same technology to make a flu vaccine.

Initially, the FDA said it wouldn't review the new shot because the company didn't compare it to a high-dose flu vaccine in older people.

Now, Moderna says it will take an aged-based approach and agree to add a confirmatory study after marketing begins that will focus on older adults.

The company says the new vaccine would be ready for the next flu season pending FDA approval.

Support for Today Explained comes from Pepsi.

Maybe you heard this one.

In 2025, Pepsi brought back the Pepsi Challenge, where in blind taste tests, participants were given two zero sugar colas and they had to choose which taste they preferred.

The data, no less, shows that 66% of participants chose Pepsi zero sugar over Coke zero sugar and Pepsi zero sugar won 100% of markets where Pepsi conducted the Pepsi Challenge, even in Coke's hometown of Atlanta.